Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

Core Points - Cara Therapeutics, Inc. announced a 1-for-12 reverse stock split effective December 30, 2024, reducing the number of outstanding shares from approximately 54.9 million to about 4.6 million [2][4] - The total number of authorized shares will decrease from 200 million to 16,666,667 [2][4] - The reverse stock split aims to help the company regain compliance with Nasdaq's minimum bid price requirement [3][8] Company Overview - Cara Therapeutics is a biopharmaceutical company focused on treating pruritus, with an approved IV formulation of difelikefalin for moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis [7]